新冠疫苗第二剂后六个月有效性减弱:基于链接电子健康记录的OpenSAFELY队列研究
该队列研究纳入未感染过SARS-CoV-2的成年人,比较接种两剂BNT162b2或ChAdOx1者与未接种者,每四周评估一次疫苗有效性。结果显示疫苗有效性随时间减弱,但第二剂后26周内对住院和死亡的保护仍较高;至23-26周,接种者阳性检测率与未接种者相似或更高。
要点
- 第二剂后26周内,BNT162b2对住院和死亡的有效性估计≥80%,ChAdOx1≥75%。
- ≥65岁亚组每四周住院、死亡和阳性检测的调整风险比比值范围为1.19至1.34。
- 至23-26周,接种者阳性检测率与未接种者相似或更高,BNT162b2调整风险比最高1.72,ChAdOx1最高1.86。
核心结论
- 疫苗有效性对住院、死亡和阳性检测的减弱速率一致,且在不同年龄和临床脆弱性亚组间相似。
研究设计与样本
- OpenSAFELY-TPP数据库链接初级保健、医院和新冠记录,经NHS England批准的队列研究。
- 纳入无既往SARS-CoV-2感染的成年人,排除养老院居民和医护人员。
- 1 951 866人接种两剂BNT162b2,3 219 349人接种两剂ChAdOx1,2 422 980人未接种。
- 每四周一个比较期,共六个比较期,比较接种者与未接种者的调整风险比。
主要发现
- ≥65岁亚组每四周新冠住院、新冠死亡和阳性SARS-CoV-2检测的调整风险比比值范围为1.19(95%CI 1.14至1.24)至1.34(95%CI 1.09至1.64)。
- 第二剂后26周内,接种者新冠住院和死亡率仍显著低于未接种者,BNT162b2有效性估计≥80%,ChAdOx1≥75%。
- 至23-26周,接种者阳性SARS-CoV-2检测率与未接种者相似或更高,BNT162b2调整风险比最高1.72(95%CI 1.11至2.68),ChAdOx1最高1.86(95%CI 1.79至1.93)。
临床怎么用
- 第二剂后26周内疫苗对住院和死亡保护仍较高,支持在此时窗内安排加强接种。
- 至23-26周阳性检测保护减弱,接种者阳性率与未接种者相似或更高,应关注感染风险变化。
局限性
- 研究结论基于原始毒株数据,若持续至奥密克戎变异株感染和加强接种,将有助于安排加强接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate waning of covid-19 vaccine effectiveness over six months after second dose. DESIGN: Cohort study, approved by NHS England. SETTING: Linked primary care, hospital, and covid-19 records within the OpenSAFELY-TPP database. PARTICIPANTS: Adults without previous SARS-CoV-2 infection were eligible, excluding care home residents and healthcare professionals. EXPOSURES: People who had received two doses of BNT162b2 or ChAdOx1 (administered during the national vaccine rollout) were compared with unvaccinated people during six consecutive comparison periods, each of four weeks. MAIN OUTCOME MEASURES: Adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, positive SARS-CoV-2 test, and non-covid-19 related death comparing vaccinated with unvaccinated people. Waning vaccine effectiveness was quantified as ratios of adjusted hazard ratios per four week period, separately for subgroups aged ≥65 years, 18-64 years and clinically vulnerable, 40-64 years, and 18-39 years. RESULTS: 1 951 866 and 3 219 349 eligible adults received two doses of BNT162b2 and ChAdOx1, respectively, and 2 422 980 remained unvaccinated. Waning of vaccine effectiveness was estimated to be similar across outcomes and vaccine brands. In the ≥65 years subgroup, ratios of adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test ranged from 1.19 (95% confidence interval 1.14 to 1.24)to 1.34 (1.09 to 1.64) per four weeks. Despite waning vaccine effectiveness, rates of covid-19 related hospital admission and death were substantially lower among vaccinated than unvaccinated adults up to 26 weeks after the second dose, with estimated vaccine effectiveness ≥80% for BNT162b2, and ≥75% for ChAdOx1. By weeks 23-26, rates of positive SARS-CoV-2 test in vaccinated people were similar to or higher than in unvaccinated people (adjusted hazard ratios up to 1.72 (1.11 to 2.68) for BNT162b2 and 1.86 (1.79 to 1.93) for ChAdOx1). CONCLUSIONS: The rate at which estimated vaccine effectiveness waned was consistent for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test and was similar across subgroups defined by age and clinical vulnerability. If sustained to outcomes of infection with the omicron variant and to booster vaccination, these findings will facilitate scheduling of booster vaccination.
引用
- Horne EMF, Hulme WJ, Keogh RH, et al. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. BMJ. 2022. PMID: 35858698. doi:10.1136/bmj-2022-071249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。